-

Kirby McInerney LLP Reminds Hims & Hers Health, Inc. (HIMS) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) securities during the period of April 29, 2025, through June 23, 2025, inclusive (“the Class Period”). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

[LEARN MORE ABOUT THE CLASS ACTION]

On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” under which Hims & Hers would sell Novo Nordisk’s popular weight loss drug Wegovy. On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in “deceptive marketing” and the illegal “selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” On this news, the price of Hims & Hers shares declined $22.25 per share, or approximately 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025.

The lawsuit alleges that Hims & Hers failed to disclose to investors that: (1) the Company was engaged in the deceptive promotion and sale of illegitimate, knockoff versions of Wegovy that endangered patients; and (2) as a result, there was a substantial risk that the Company’s collaboration with Novo Nordisk would be terminated.

If you purchased or otherwise acquired Hims & Hers securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters without any cost to you.

[CONTACT FORM]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NYSE:HIMS

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

INVESTOR ALERT: Kirby McInerney LLP Files A Securities Class Action Lawsuit Against Camping World Holdings, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that it has filed a class action, Siverd v. Camping World Holdings, Inc. et al., No. 26 Civ. 2710, in the United States District Court for the Northern District of Illinois on behalf of investors who acquired Camping World Holdings, Inc. (“Camping World” or the “Company”) (NYSE:CWH) securities during the period of April 29, 2025 through February 24, 2026, inclusive (“the Class Period”). If you suffered a loss on your Campi...

BYND DEADLINE NOTICE: Beyond Meat, Inc. Investors Encouraged to Contact Kirby McInerney LLP By March 24, 2026

NEW YORK--(BUSINESS WIRE)--If you suffered a loss on your investment in Beyond Meat, Inc. (“Beyond Meat” or the “Company”) (NASDAQ:BYND), contact Lauren Molinaro by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until March 24, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff o...

REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ:CORT) investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual i...
Back to Newsroom